. Author manuscript; available in PMC: 2013 May 13.

Published in final edited form as: Cancer. 2008 Apr 15;112(8):1754–1764. doi: 10.1002/cncr.23327

TABLE 4.

Cox Regression Analyses of Favorable Features Associated With Duration of Complete Response, Event-free Survival, and Overall Survival for Non-Total Therapy Patients: Multivariate Analysis With Treatment

Favorable parameter	No. with factor/no. with valid data for factor (%)	OS		EFS		Duration of CR
Favorable parameter	No. with factor/no. with valid data for factor (%)	HR [95% CI]	P^*	HR [95% CI]	P^*	No. with factor/no. with valid data for factor (%)	HR [95% CI]	P^*
No CA13/hypodiploidy	1240/1667 (74)	0.47 [0.41–0.54]	<.001	0.59 [0.52–0.67]	<.001	577/775 (74)	0.55 [0.45–0.68]	<.001
Platelets ≥100,000/μL	1416/1667 (85)	0.51 [0.42–0.60]	<.001	0.59 [0.51–0.70]	<.001	682/775 (88)	0.51 [0.39–0.68]	<.001
Albumin ≥3.0 /g/dL	1464/1667 (88)	0.61 [0.51–0.73]	<.001	0.57 [0.48–0.67]	<.001	712/775 (92)	0.65 [0.48–0.89]	.007
B₂M <3.0 mg/L	1003/1667 (60)	0.67 [0.58–0.76]	<.001	0.71 [0.63–0.80]	<.001	504/775 (65)	0.71 [0.59–0.86]	<.001
CRP <6.0 mg/dL	959/1667 (58)	0.79 [0.69–0.90]	<.001	0.86 [0.77–0.97]	.014	438/775 (57)	0.82 [0.68–0.99]	.036
Non-TT protocol	910/1667 (55)	0.84 [0.74–0.96]	.010	0.82 [0.72–0.92]	<.001	434/775 (56)	0.94 [0.77–1.13]	.492
Any CR^†		0.84 [0.73–0.96]	.009	0.72 [0.64–0.82]	<.001	—	—	—
Any second transplant^†		0.92 [0.80–1.07]	.302	0.82 [0.72–0.94]	.004	—	—	—

OS indicates overall survival; EFS, event-free survival; CR, complete response; HR, hazard ratio; 95% CI, 95% confidence interval; CA, cytogenetic abnormality; B₂M, β-₂-microglobulin; CRP, C-reactive protein; TT. Total Therapy.

P values were derived from the Wald chi-square test in Cox regression analysis.

^†

Time-dependent covariate.